Boston Scientific (BSX)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$44.80-1.09%
Close 2026-07-08 · 1-day change
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on growth in the cardiovascular segment. The current thesis state is intact, supported by strong recent financial performance and management's commitment to strategic execution.
The market currently prices BSX as cheap compared to its peers, with a notable expectations gap. However, there is a fragility due to weak execution quality, which suggests that the market is not fully accounting for potential risks.
Management is on track with priorities to drive net sales growth and expand the cardiovascular segment, which has shown strong growth recently. The near-term risk of missing earnings is low but should be monitored, especially given the industry's high miss rate.
The long-term thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could provide momentum for BSX. Conversely, any negative guidance from these peers could impact BSX's outlook.
Overall, BSX has a solid foundation for growth but must navigate sector dynamics carefully. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. On one hand, the latest earnings beat supports the view that the company's fundamentals are holding strong. On the other hand, a nationwide recall of Orca valves raises concerns about product reliability and could impact sales growth.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Finishing the share buyback could show trust in the company's finances. It could also help shareholders.
Confirms:The ASR is completed by June 30, 2026, with shares repurchased as planned.
Disproves:The ASR is late or done with many fewer shares than expected.
Why it matters: Hitting or beating earnings guidance would show management's trust and growth plans.
Confirms:Q2 2026 adjusted EPS reported at or above the guided range of $0.82 to $0.84.
Disproves:Q2 2026 adjusted EPS reported below the guided range.
Why it matters: Good results could help Boston Scientific grow in the heart market. It could also improve its products.
Confirms:The STAR trial shows good safety and effectiveness for the SIEGEL TAVR valve.
Disproves:The STAR trial shows bad results or major safety issues.
Why it matters: The STAR trial will show if the SIEGEL TAVR valve is safe and effective. Positive results could boost Boston Scientific's cardiovascular segment.
Confirms:The STAR trial shows safe and effective results for patients with aortic stenosis.
Disproves:The STAR trial shows safety or effectiveness problems.
Why it matters: Meeting or exceeding the sales growth guidance would confirm strong demand and execution. This may support a positive outlook.
Confirms:Q2 2026 net sales growth reported between 5.5% and 7.5% on a reported basis.
Disproves:Q2 2026 net sales growth falls below 5.5% on a reported basis.
Why it matters: Steady growth in this area is key for Boston Scientific's success and market strength.
Confirms:Cardiovascular growth was at or above 11% in Q2 2026.
Disproves:Cardiovascular growth was below 10% in Q2 2026.